Skip to main content
David Oldach, MD, Infectious Disease, Waltham, MA

DavidWOldachMD

Infectious Disease Waltham, MA

Chief Medical Officer, Visterra, Inc

Dr. Oldach is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Oldach's full profile

Already have an account?

  • Office

    Visterra, Inc.
    275 2nd Avenue
    Waltham, MA 02451
    Phone+1 617-401-2026

Summary

  • I am a Board Certified Infectious Disease Physician. After 18 years on faculty at the University of Maryland School of Medicine/Institute of Human Virology, I moved into drug development. First as Director in Clinical Development at Gilead (HCV/HBV), then as CMO at Cempra (antibiotics), currently as CMO at Visterra, an MIT-spinout monoclonal antibody developer (and now an Otsuka subsidiary). Visterra's focus is on developing better biologics for diseases of inflammation and immunity, focused principally on kidney disease, also with ongoing programs in selected infectious diseases.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Infectious Disease, 1989 - 1992
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1986 - 1989
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 1986

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1989 - 2025
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza A
    Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza ANovember 15th, 2018
  • Visterra Initiates Phase 1 Clinical Study of VIS649
    Visterra Initiates Phase 1 Clinical Study of VIS649November 8th, 2018
  • Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Respiratory Pathogens
    Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Respiratory PathogensMarch 7th, 2018
  • Join now to see all

Grant Support

  • Needlestick HCV Exposure: Virologic &Immunologic EventsNational Institute Of Allergy And Infectious Diseases2000–2003
  • Needlestick HCV Exposure--Virologic &Immunologic EventsNational Institute Of Allergy And Infectious Diseases1999
  • Needlestick HCV Exposure Among Health Care WorkersNational Institute Of Allergy And Infectious Diseases1998–1999
  • Murine Model For Hepatitis C Virus InvestigationsNational Institute Of Allergy And Infectious Diseases1996–1998